Dysphagia RehabilitationRESA-SWALLOWNCT07546045
Personalized Rehabilitation With Organ-Preserving Robotic RESA in Head and Neck Cancer
A study testing Intensive and Personalized Speech, Swallowing, and Voice Rehabilitation (SSVR) in people with Dysphagia Rehabilitation, run by Christian Simon at 1 site in Switzerland.
Trial summary
This study aims to evaluate whether an intensive and personalized speech, swallowing, and voice rehabilitation (SSVR) program can help preserve swallowing function in patients with head and neck cancer undergoing minimally invasive robotic-assisted extended "Sistrunk" surgery (RESA). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Dysphagia Rehabilitation
- What is being tested?
- Intensive and Personalized Speech, Swallowing, and Voice Rehabilitation (SSVR)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 53 participants
- Where
- 1 siteSwitzerland
- Study dates
- May 2026to May 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients scheduled for a surgery with robotic-assisted extended "Sistrunk" approach - multiport (RESA) with the Da Vinci Xi or SP robotic system for:
- a primary tumor resection of (cohort 1) i. oropharyngeal (base of tongue with involvement of the vallecula) (T1-3) or ii. hypopharyngeal (piriform sinus, posterior hypopharyngeal wall, postcricoid region) (T1-2) or iii. supraglottis (epiglottis, false cord, aryepiglottic fold) (T1-3) (no cord fixation) or iv. glottis (HPV + and HPV -) squamous cell carcinoma of the upper aerodigestive tract, or
- a tumor resection of recurrent or second primary of (cohort 2) i. oropharyngeal (base of tongue with involvement of the vallecula) (T1-3) ii. hypopharyngeal (piriform sinus, posterior hypopharyngeal wall, postcricoid region) (T1-2) iii. supraglottis (epiglottis, false cord, aryepiglottic fold) (T1-3) (no cord fixation) iv. glottis (HPV + and HPV -) squamous cell carcinoma of the upper aerodigestive tract, or
- a laryngeal elevation aiming at improving dysphagia (cohort 3) i. in patients formerly treated for HNC and, ii. free of HNC for at least 2 years and, iii. with preserved vocal cord mobility assessed by videostroboscopy and, iv. with a MDADI ≤60 assessed at screening visit, v. with a PAS ≥ 5 assessed at screening visit by FEES vi. a minimum of 20 speech, swallowing and voice rehabilitation therapy sessions have already been carried out
- Indication for speech, swallowing and voice rehabilitation after surgery
- Informed consent signature
- 18 years old or older at the time of informed consent signature
Who cannot join
- Inability to give informed consent
- Inability to follow study procedures (FEES, VFSS, questionnaires, "intensive" SSVR or else)
- Any psychological, cognitive, familial, sociological or geographical condition potentially hampering compliance with the study protocol, completion of patient reported measures and follow-up schedule,
- Inability to memorize one analytic and one compensatory exercise at screening visit
- Participation in another study with an investigational drug or medical device within the 30 days preceding and during the present investigation,
- previous enrolment into the current study,
- contraindication to iodine contrast media (Accupaque) oral intake, i.e known anaphylaxis.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne, 1011
Jelena Todic, MD, +41(0)795560862, jelena.todic@chuv.ch
About this study
Official title: Intensive Personalized Rehabilitation Combined to Organ-Preserving Robotic-Assisted Extended "Sistrunk" Approach (RESA) to Preserve Swallowing in Head and Neck Cancer Patients: A Monocentric Clinical Trial
This study aims to evaluate whether an intensive and personalized speech, swallowing, and voice rehabilitation (SSVR) program can help preserve swallowing function in patients with head and neck cancer undergoing minimally invasive robotic-assisted extended "Sistrunk" surgery (RESA).
Participants will undergo the RESA surgery as part of their standard care. After surgery, they will receive a structured SSVR program for 12 weeks, including daily exercises performed both with a speech therapist and independently. The program is tailored to each patient and adapted based on regular assessments of swallowing and voice function.
Read more
The study includes three groups of patients:
Those having surgery for a primary tumor Those having surgery for a recurrent or second primary tumor Patients treated for laryngeal elevation to improve swallowing after previous cancer treatment
The main goal is to assess whether this approach improves swallowing function measured by a validated questionnaire 12 weeks after surgery. Secondary outcomes include long-term swallowing, voice, diet, post-operative complications, surgical success, disease recurrence, survival, and quality of life.
All participants will be followed for two years with regular visits at CHUV, including swallowing and voice tests, questionnaires, and imaging exams. The study is expected to provide important information on how combining minimally invasive surgery with intensive rehabilitation can benefit patients' swallowing and overall quality of life.
- Conditions
- Dysphagia Rehabilitation
- Being tested
- Intensive and Personalized Speech, Swallowing, and Voice Rehabilitation (SSVR)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intensive and Personalized Speech, Swallowing, and Voice Rehabilitation (SSVR)Other
Participants will receive a 12-week intensive and personalized speech, swallowing, and voice rehabilitation (SSVR) program following minimally invasive robotic-assisted extended "Sistrunk" surgery (RESA).
The program includes:
- Supervised SSVR sessions (approximately 45 minutes) with a speech therapist, starting 7 days post-surgery, once per day during hospitalization, then 1-3 times per week outpatient up to week 12.
- Unsupervised SSVR sessions (approximately 20 minutes) performed daily by the participant at home.
- Exercises are personalized and adapted regularly based on functional assessments of swallowing and voice using FEES and VFSS exams.
The goal is to improve swallowing safety and efficiency, voice quality, and overall functional outcomes.
| Study group | Role | What they receive |
|---|---|---|
| Intensive and Personalized SSVR | Experimental | All participants receive a 12-week intensive and personalized speech, swallowing, and voice rehabilitation (SSVR) program following minimally invasive robotic-assisted extended "Sistrunk" surgery (RESA). Supervised sessions with a speech therapist and unsupervised daily exercises are included. Receives: Other: Intensive and Personalized Speech, Swallowing, and Voice Rehabilitation (SSVR) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Swallowing function measured by composite MDADI score
The primary outcome is the percentage of participants reaching a composite MDADI score of 80 (cohorts 1 and 2) or 60 (cohort 3) at 12 weeks after surgery. All participants complete the MDADI questionnaire at screening and at the 12-week post-operative visit to assess swallowing function, safety, and quality of life related to dysphagia.
Measured: 12 weeks post-surgery
Secondary outcomes (30)
Long-term swallowing function - MDADI
Composite MDADI scores will be assessed at screening, 6, 12, and 24 months post-surgery to evaluate the long-term effect of intensive and personalized SSVR on swallowing function.
Measured: Up to 24 months post-surgery
Dietary intake - Functional Oral Intake Scale (FOIS)
Dietary intake will be assessed using the Functional Oral Intake Scale (FOIS), a 7-point ordinal scale ranging from 1 to 7. Score is rated on 7 when patient tolerates total normal diet with no restrictions.
Measured: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Dietary consistency - International Dysphagia Diet Standardisation Initiative (IDDSI)
Dietary consistency will be assessed using the International Dysphagia Diet Standardisation Initiative (IDDSI) framework, which classifies food and drink textures into levels ranging from 0 (thin liquids) to 7 (regular foods). Higher levels indicate more advanced diet textures.
Measured: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallowing safety - Penetration-Aspiration Scale (PAS)
Swallow safety will be assessed using the Penetration-Aspiration Scale (PAS). It is an 8-point scale (no unit) used to characterize the depth and response to airway invasion during swallowing. Higher scores indicate worse swallow safety.
Measured: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow efficiency - Eisenhuber scale
Qualitative parameters will be assessed using VFSS: recording of the total number of swallows per bolus, evaluation of residue in the valleculae and piriform sinuses with the Eisenhuber scale (0-3, no unit).
Measured: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow Reaction Time (SRT)
Swallow reaction time (SRT) will be quantitatively assessed using videofluoroscopic swallow study (VFSS). Unit of Measure: Milliseconds (ms)
Measured: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Laryngeal Vestibule Closure Reaction Time (LVCrt)
Laryngeal vestibule closure reaction time (LVCrt) will be quantitatively assessed using VFSS. Unit of Measure: Milliseconds (ms).
Measured: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Pharyngeal Transit Time (PTT)
Pharyngeal transit time (PTT) will be quantitatively assessed using VFSS. Unit of Measure: Milliseconds (ms).
Measured: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Upper Esophageal Sphincter (UES) Opening Duration
Upper esophageal sphincter (UES) opening duration will be quantitatively assessed using VFSS. Unit of Measure: Milliseconds (ms)
Measured: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow amplitude - hyoid elevation (HE)
Hyoid elevation (HE) in millimeter (mm) will be assessed using VFSS.
Measured: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow amplitude - Laryngeal ascension amplitude
Laryngeal ascension amplitude (mm) will be assessed using VFSS.
Measured: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow amplitude - normalized maximum width of upper esophageal sphincter (UES) opening
normalized maximum width of upper esophageal sphincter (UES) opening (%) will be assessed using VFSS.
Measured: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow amplitude - Pharyngeal area at maximum dilation
Pharyngeal area at maximum dilation (cm²) will be assessed using VFSS.
Measured: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow amplitude - Pharyngeal constriction ratio
Pharyngeal constriction ratio (PCR, %) will be assessed using VFSS.
Measured: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow efficiency - Normalized Residue Ratio Scale valleculae (NRRSv)
Swallow efficiency: measured with the Normalized Residue Ratio Scale valleculae (NRRSv)
Measured: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow efficiency - Normalized Residue Ratio Scale piriform (NRRSp)
Swallow efficiency: measured with the Normalized Residue Ratio Scale piriform (NRRSp)
Measured: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Voice quality - GRBAS scale
Voice will be assessed at screening, weeks 4, 12, and months 6, 12, 24 using the GRBAS scale : (G(rade) of hoarseness, R(oughness), B(reathliness), A(esthenia) weakness, and S(train).
Measured: Up to 24 months post-surgery
Voice quality - Maximum Phonation Time (MPT)
Voice will be assessed at screening, weeks 4, 12, and months 6, 12, 24 using the Maximum Phonation Time (MPT) (seconds).
Measured: Up to 24 months post-surgery
Voice quality - Jitter (variations in signal frequency)
Voice will be assessed at screening, weeks 4, 12, and months 6, 12, 24 using the Jitter (variations in signal frequency) %.
Measured: Up to 24 months post-surgery
Voice quality - Shimmer (variation in signal amplitude)
Voice will be assessed at screening, weeks 4, 12, and months 6, 12, 24 using the Shimmer (variation in signal amplitude) %.
Measured: Up to 24 months post-surgery
Post-operative complications - Clavien-Dindo
Post-operative complications will be assessed using the Clavien-Dindo classification, a grading system ranging of 7 grades (I, II, IIIa, IIIb, IVa, IVb and V) and if the patient suffers from a complication at the time of discharge, the suffix "d" (for "disability") is added to the respective grade of complication. The grade I corresponds to any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic, and radiological intervention and the grade V corresponds to the death of the patient.
Measured: from week 0 to 12
Post-operative complication - Postoperative Hemorrhage
Classification System for Postoperative Hemorrhage is graded as normal, minor, intermediate, major, or severe. The definition of normal is patient noting the presence of blood tinged mucus, flecks of blood, brown mucus, or red streaks, and the severe bleeding corresponds to bleeding resulting in life-threatening medical complications.
Measured: From week 0 to week 1
Loco-regional recurrence
Local-regional control is defined as the time interval between the date of the 3-month mandatory imaging after the surgery and the date of local disease is detected. Local recurrence is defined as recurrence at the original primary tumor subsite or within 2 cm of distance from the primary tumor site. Regional recurrence is defined as recurrence at the cervical lymph node. The Time to first loco-regional recurrence (months) is assessed for cohorts 1 and 2.
Measured: Up to 24 months post-surgery
Distant tumor recurrence
distant control is defined as the time interval between the date of the 3-month mandatory imaging if the patient after the surgery and the first date when distant disease is detected. Distant recurrence is defined as recurrence not considered as local or regional. Time to first distant recurrence (months) is assessed for cohorts 1 and 2.
Measured: Up to 24 months post-surgery
2nd primary head and neck cancer (HNC) control
Second primary head and neck cancer control is defined as the time interval between the date of surgery and the date of diagnosis of a second cancer in the head and neck region, but outside the original primary tumor subsite (months) for cohorts 1 and 2.
Measured: Up to 24 months post-surgery
Disease-free survival (DFS)
Disease-free survival is defined as the time interval between the date of surgery and tumor recurrence or death from any cause (months) for cohort 1 and 2.
Measured: Up to 24 months post-surgery
Disease-specific survival
Disease-specific survival is defined as the time interval between the date of surgery and the date of death due to original primary disease (months) for cohort 1 and 2.
Measured: Up to 24 months post-surgery
Overall survival (OS)
Overall survival is defined as the time interval between the date of surgery and the date of death from any cause (months) for cohort 1 and 2.
Measured: Up to 24 months post-surgery
Surgical margin status
Percentage of participants with negative (>3 mm), close (1-3 mm), and positive (<1 mm) surgical margins will be recorded post-surgery.
Measured: Week 0 post-surgery
Quality of life - EORTC QLQ-HN43
Participants will complete the EORTC QLQ-HN43 questionnaire at screening, week 12, and months 6, 12, 24 to assess health-related quality of life.
Measured: Up to 24 months post-surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2026
- Study startMay 2026 (estimated)
- Primary completionAug 2028 (estimated)
- Study completionMay 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dysphagia RehabilitationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 53 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Christian Simon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Christian Simon, Centre Hospitalier Universitaire Vaudois
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07546045
- Sponsor's protocol ID
- 2025-01892
- Other IDs
- 2025
- Acronym
- RESA-SWALLOW
- Status last verified
- May 2026
- First submitted
- 31 Mar 2026
- Last updated
- 12 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intensive Personalized Rehabilitation Combined to Organ-Preserving Robotic-Assisted Extended "Sistrunk" Approach (RESA) to Preserve Swallowing in Head and Neck Cancer Patients: A Monocentric Clinical Trial
- ClinicalTrials.gov ID
- NCT07546045
- Acronym / sponsor ID
- RESA-SWALLOW / 2025-01892
- Conditions
- Dysphagia Rehabilitation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 53 participants (estimated)
- Lead sponsor
- Christian SimonUniversity, hospital or other
- Study start
- May 2026 (estimated)
- Primary completion
- Aug 2028 (estimated)
- Study completion
- May 2030 (estimated)
- First posted
- 22 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate whether an intensive and personalized speech, swallowing, and voice rehabilitation (SSVR) program can help preserve swallowing function in patients with head and neck cancer undergoing minimally invasive robotic-assisted extended "Sistrunk" surgery (RESA).
Participants will undergo the RESA surgery as part of their standard care. After surgery, they will receive a structured SSVR program for 12 weeks, including daily exercises performed both with a speech therapist and independently. The program is tailored to each patient and adapted based on regular assessments of swallowing and voice function.
The study includes three groups of patients:
Those having surgery for a primary tumor Those having surgery for a recurrent or second primary tumor Patients treated for laryngeal elevation to improve swallowing after previous cancer treatment
The main goal is to assess whether this approach improves swallowing function measured by a validated questionnaire 12 weeks after surgery. Secondary outcomes include long-term swallowing, voice, diet, post-operative complications, surgical success, disease recurrence, survival, and quality of life.
All participants will be followed for two years with regular visits at CHUV, including swallowing and voice tests, questionnaires, and imaging exams. The study is expected to provide important information on how combining minimally invasive surgery with intensive rehabilitation can benefit patients' swallowing and overall quality of life.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Intensive and Personalized SSVR | Experimental | Other: Intensive and Personalized Speech, Swallowing, and Voice Rehabilitation (SSVR)All participants receive a 12-week intensive and personalized speech, swallowing, and voice rehabilitation (SSVR) program following minimally invasive robotic-assisted extended "Sistrunk" surgery (RESA). Supervised sessions with a speech therapist and unsupervised daily exercises are included. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patients scheduled for a surgery with robotic-assisted extended "Sistrunk" approach - multiport (RESA) with the Da Vinci Xi or SP robotic system for:
- Indication for speech, swallowing and voice rehabilitation after surgery
- Informed consent signature
- 18 years old or older at the time of informed consent signature
Key exclusion criteria (7 listed)
- Inability to give informed consent
- Inability to follow study procedures (FEES, VFSS, questionnaires, "intensive" SSVR or else)
- Any psychological, cognitive, familial, sociological or geographical condition potentially hampering compliance with the study protocol, completion of patient reported measures and follow-up schedule,
- Inability to memorize one analytic and one compensatory exercise at screening visit
- Participation in another study with an investigational drug or medical device within the 30 days preceding and during the present investigation,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intensive and Personalized Speech, Swallowing, and Voice Rehabilitation (SSVR)Participants will receive a 12-week intensive and personalized speech, swallowing, and voice rehabilitation (SSVR) program following minimally invasive robotic-assisted extended "Sistrunk" surgery (RESA). The program includes: * Supervised SSVR sessions (approximately 45 minutes) with a speech therapist, starting 7 days post-surgery, once per day during hospitalization, then 1-3 times per week outpatient up to week 12. * Unsupervised SSVR sessions (approximately 20 minutes) performed daily by the participant at home. * Exercises are personalized and adapted regularly based on functional assessments of swallowing and voice using FEES and VFSS exams. The goal is to improve swallowing safety and efficiency, voice quality, and overall functional outcomes. | Other | Intensive and Personalized SSVR |
Primary outcome
Swallowing function measured by composite MDADI score
Time frame: 12 weeks post-surgery
The primary outcome is the percentage of participants reaching a composite MDADI score of 80 (cohorts 1 and 2) or 60 (cohort 3) at 12 weeks after surgery. All participants complete the MDADI questionnaire at screening and at the 12-week post-operative visit to assess swallowing function, safety, and quality of life related to dysphagia.
30 secondary outcomes
Long-term swallowing function - MDADI
Time frame: Up to 24 months post-surgery
Dietary intake - Functional Oral Intake Scale (FOIS)
Time frame: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Dietary consistency - International Dysphagia Diet Standardisation Initiative (IDDSI)
Time frame: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallowing safety - Penetration-Aspiration Scale (PAS)
Time frame: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow efficiency - Eisenhuber scale
Time frame: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow Reaction Time (SRT)
Time frame: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Laryngeal Vestibule Closure Reaction Time (LVCrt)
Time frame: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Pharyngeal Transit Time (PTT)
Time frame: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Upper Esophageal Sphincter (UES) Opening Duration
Time frame: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow amplitude - hyoid elevation (HE)
Time frame: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow amplitude - Laryngeal ascension amplitude
Time frame: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow amplitude - normalized maximum width of upper esophageal sphincter (UES) opening
Time frame: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow amplitude - Pharyngeal area at maximum dilation
Time frame: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow amplitude - Pharyngeal constriction ratio
Time frame: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow efficiency - Normalized Residue Ratio Scale valleculae (NRRSv)
Time frame: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Swallow efficiency - Normalized Residue Ratio Scale piriform (NRRSp)
Time frame: Up to 24 months post-surgery (assessed at screening, weeks 1, 4, 12, and months 6, 12, 24)
Voice quality - GRBAS scale
Time frame: Up to 24 months post-surgery
Voice quality - Maximum Phonation Time (MPT)
Time frame: Up to 24 months post-surgery
Voice quality - Jitter (variations in signal frequency)
Time frame: Up to 24 months post-surgery
Voice quality - Shimmer (variation in signal amplitude)
Time frame: Up to 24 months post-surgery
Post-operative complications - Clavien-Dindo
Time frame: from week 0 to 12
Post-operative complication - Postoperative Hemorrhage
Time frame: From week 0 to week 1
Loco-regional recurrence
Time frame: Up to 24 months post-surgery
Distant tumor recurrence
Time frame: Up to 24 months post-surgery
2nd primary head and neck cancer (HNC) control
Time frame: Up to 24 months post-surgery
Disease-free survival (DFS)
Time frame: Up to 24 months post-surgery
Disease-specific survival
Time frame: Up to 24 months post-surgery
Overall survival (OS)
Time frame: Up to 24 months post-surgery
Surgical margin status
Time frame: Week 0 post-surgery
Quality of life - EORTC QLQ-HN43
Time frame: Up to 24 months post-surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 May 2026.
- Individual participant dataSharing planned: No
Related trials for Dysphagia Rehabilitation
Recruiting
The Effectiveness of Structured Swallowing Exercise Therapy in Patients With Nasopharyngeal Carcinoma: An Assessment of Swallowing Function and Quality of Life
Nasopharyngeal Carcinoma (NPC)
Not yet recruiting
EEG Feedback-Based Vagus Nerve Stimulation for Post-Stroke Dysphagia
Ischemic Stroke, Post-stroke Dysphagia
RecruitingPhase 2
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
Dysphagia, Stroke
RecruitingPhase 2
Rehabilitation of Airway Protection in Parkinson's Disease
Parkinson Disease, Dysphagia
Recruiting
Swallowing Rehabilitation Program for Head and Neck Tumor Patients
Head and Neck Cancer (H&N)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Intensive and Personalized Speech, Swallowing, and Voice Rehabilitation (SSVR) in people with Dysphagia Rehabilitation, run by Christian Simon at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jelena Todic (+41(0)79 556 08 62, jelena.todic@chuv.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Swallowing function measured by composite MDADI score (time frame: 12 weeks post-surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2026.